MedDataX Logo

Endocrine Regulation of Lipolysis in Obesity and Diabetes

NCT ID: NCT02598544

Last Updated: 2016-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adipose tissue (AT) dysfunction is a commonly observed feature of metabolic dysfunction in obesity and diabetes. An important characteristic when examining AT function is the capacity to break down stored lipids (i.e. lipolysis) and its regulation. In the present study, the aim was to investigate whether atrial natriuretic peptide-mediated lipolysis is altered in different adipose tissue depots (subcutaneous and visceral adipose tissue) of obese subjects with or without type 2 diabetes, compared to age-matched lean men. Eventually, the knowledge gained from this research will contribute to a better understanding of the present adipose tissue dysfunction and to the optimization of exercise programs for people with obesity and diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lean men

Group Type OTHER

adipose tissue sampling

Intervention Type OTHER

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Obese men without type 2 diabetes

Group Type OTHER

adipose tissue sampling

Intervention Type OTHER

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Obese men with type 2 diabetes

Group Type OTHER

adipose tissue sampling

Intervention Type OTHER

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adipose tissue sampling

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lean group: BMI \< 25 kg/m², insulin sensitive (HOMA-Insuline Resistance (IR) \< 2.3), age 40-65
* Obese groups: BMI \> 30 kg/m², presence or absence of type 2 diabetes based on use of glucose lowering medication or HbA1c \> 6.5%, age 40-65

Exclusion Criteria

* presence of a history of heart, lung or kidney disease and/or presence of endocrine anomalies. Use of beta-blockade medication.
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jessa Hospital

OTHER

Sponsor Role collaborator

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dominique Hansen

prof. dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dominique Hansen, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Hasselt University

Ellen Blaak, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Kenneth Verboven, drs.

Role: STUDY_CHAIR

Hasselt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hasselt University

Diepenbeek, , Belgium

Site Status

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

Jessa Ziekenhuis

Hasselt, , Belgium

Site Status

Maastricht University

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14.17/REVA14.02

Identifier Type: -

Identifier Source: org_study_id